$PALI
PALISADE BIO, INC.

2013 Q3 Form 10-Q Financial Statement

#000114420413043952 Filed on August 08, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $2.500K $2.500K $78.13K
YoY Change -98.54% -96.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.710M $1.280M $820.0K
YoY Change 33.59% 56.1% -46.05%
% of Gross Profit
Research & Development $1.847M $1.906M $1.599M
YoY Change 33.34% 19.25% -23.51%
% of Gross Profit
Depreciation & Amortization $80.00K $50.00K $50.00K
YoY Change 0.0% 0.0% -16.67%
% of Gross Profit
Operating Expenses $3.636M $3.238M $2.461M
YoY Change 32.04% 31.56% -32.93%
Operating Profit -$3.634M -$3.236M -$2.383M
YoY Change 40.68% 35.76%
Interest Expense $448.9K $439.3K $601.00
YoY Change 133912.84% 72990.02% -97.0%
% of Operating Profit
Other Income/Expense, Net -$3.053M -$3.016M $6.874K
YoY Change -53029.46% -43975.88%
Pretax Income -$6.690M -$6.250M -$2.380M
YoY Change 159.3% 162.61% -34.79%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.687M -$6.252M -$2.376M
YoY Change 159.45% 163.07% -34.89%
Net Earnings / Revenue -267478.28% -250065.2% -3041.77%
Basic Earnings Per Share
Diluted Earnings Per Share -$133.8M -$156.3M -$79.33M
COMMON SHARES
Basic Shares Outstanding 71.65M shares 54.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.40M $11.17M $2.540M
YoY Change 66.16% 339.76% -58.63%
Cash & Equivalents $16.40M $11.17M $2.540M
Short-Term Investments
Other Short-Term Assets $920.0K $810.0K $290.0K
YoY Change 217.24% 179.31% -6.45%
Inventory
Prepaid Expenses $344.0K $156.6K
Receivables $7.500K $56.76K
Other Receivables $0.00
Total Short-Term Assets $17.33M $11.97M $2.830M
YoY Change 70.56% 323.01% -56.12%
LONG-TERM ASSETS
Property, Plant & Equipment $253.6K $189.8K $270.0K
YoY Change 1.42% -29.7% -20.59%
Goodwill
YoY Change
Intangibles $1.048M $984.9K
YoY Change
Long-Term Investments
YoY Change
Other Assets $64.86K $59.57K $60.00K
YoY Change 8.1% -0.72% -14.29%
Total Long-Term Assets $1.837M $1.827M $1.130M
YoY Change 70.1% 61.67% 16.49%
TOTAL ASSETS
Total Short-Term Assets $17.33M $11.97M $2.830M
Total Long-Term Assets $1.837M $1.827M $1.130M
Total Assets $19.17M $13.80M $3.960M
YoY Change 70.51% 248.44% -46.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.210M $810.0K $1.150M
YoY Change -19.33% -29.57% 49.35%
Accrued Expenses $460.0K $310.0K $320.0K
YoY Change -4.17% -3.13% -15.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.986M $1.236M
YoY Change
Total Short-Term Liabilities $5.148M $3.006M $1.470M
YoY Change 142.82% 104.5% 27.83%
LONG-TERM LIABILITIES
Long-Term Debt $5.661M $6.364M $0.00
YoY Change
Other Long-Term Liabilities $90.00K $60.00K
YoY Change 350.0%
Total Long-Term Liabilities $5.661M $6.364M $0.00
YoY Change 28206.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.148M $3.006M $1.470M
Total Long-Term Liabilities $5.661M $6.364M $0.00
Total Liabilities $10.90M $9.425M $1.470M
YoY Change 409.29% 541.19% 27.83%
SHAREHOLDERS EQUITY
Retained Earnings -$125.1M -$118.4M
YoY Change
Common Stock $766.6K $706.1K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.267M $4.413M $2.490M
YoY Change
Total Liabilities & Shareholders Equity $19.17M $13.80M $3.960M
YoY Change 70.51% 248.44% -46.63%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$6.687M -$6.252M -$2.376M
YoY Change 159.45% 163.07% -34.89%
Depreciation, Depletion And Amortization $80.00K $50.00K $50.00K
YoY Change 0.0% 0.0% -16.67%
Cash From Operating Activities -$2.250M -$3.360M -$2.440M
YoY Change 58.45% 37.7% 10.41%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$140.0K -$120.0K
YoY Change 400.0% 16.67% -40.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$200.0K -$140.0K -$120.0K
YoY Change 400.0% 16.67% -40.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.680M 2.000M -40.00K
YoY Change -12.63% -5100.0%
NET CHANGE
Cash From Operating Activities -2.250M -3.360M -2.440M
Cash From Investing Activities -200.0K -140.0K -120.0K
Cash From Financing Activities 7.680M 2.000M -40.00K
Net Change In Cash 5.230M -1.500M -2.600M
YoY Change -28.65% -42.31% 7.88%
FREE CASH FLOW
Cash From Operating Activities -$2.250M -$3.360M -$2.440M
Capital Expenditures -$200.0K -$140.0K -$120.0K
Free Cash Flow -$2.050M -$3.220M -$2.320M
YoY Change 48.55% 38.79% 15.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Trading Symbol
TradingSymbol
CUR
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71648968 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
-4846471 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
26560 USD
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118435892 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
4412641 USD
dei Entity Registrant Name
EntityRegistrantName
Neuralstem, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001357459
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1756303 USD
CY2013Q2 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
55590 USD
CY2012Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
21143 USD
CY2013Q2 us-gaap Liabilities
Liabilities
9425461 USD
CY2012Q4 us-gaap Liabilities
Liabilities
1777446 USD
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
706064 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
681893 USD
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
122142469 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
114884915 USD
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000 shares
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70606448 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68189314 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11166077 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7443773 USD
CY2013Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
56755 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3333 USD
CY2013Q2 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
591847 USD
CY2012Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0 USD
CY2013Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
156592 USD
CY2012Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
205651 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
11971271 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
7652757 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
189817 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
230397 USD
CY2013Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
984946 USD
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
807357 USD
CY2013Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
592500 USD
CY2012Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0 USD
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
59568 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
59568 USD
CY2013Q2 us-gaap Assets
Assets
13798102 USD
CY2012Q4 us-gaap Assets
Assets
8750079 USD
CY2013Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
812841 USD
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1199662 USD
CY2013Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
313088 USD
CY2012Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
465865 USD
CY2013Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1235636 USD
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2013Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
633997 USD
CY2012Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2013Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10633 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
90776 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3006195 USD
us-gaap Revenues
Revenues
234375 USD
us-gaap Revenues
Revenues
105000 USD
cur Warrant Modification Expense
WarrantModificationExpense
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
181799 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3714335 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17309 USD
us-gaap Net Income Loss
NetIncomeLoss
-9841717 USD
us-gaap Net Income Loss
NetIncomeLoss
-4829162 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69591602 shares
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108594175 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
6972633 USD
CY2013Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6363676 USD
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13798102 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8750079 USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3654734 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3021060 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2477050 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1983540 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
100598 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
76246 USD
us-gaap Operating Expenses
OperatingExpenses
6232382 USD
us-gaap Operating Expenses
OperatingExpenses
5080846 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6127382 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
16190 USD
us-gaap Interest Expense
InterestExpense
487528 USD
us-gaap Interest Expense
InterestExpense
1454 USD
cur Warrant Modification Expense
WarrantModificationExpense
3071942 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52759811 shares
CY2013Q2 us-gaap Revenues
Revenues
2500 USD
CY2012Q2 us-gaap Revenues
Revenues
78125 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1906387 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1598696 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1281210 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
821384 USD
CY2013Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
50505 USD
CY2012Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
41300 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
3238102 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
2461380 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3235602 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2383255 USD
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
16635 USD
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
7475 USD
CY2013Q2 us-gaap Interest Expense
InterestExpense
439271 USD
CY2012Q2 us-gaap Interest Expense
InterestExpense
601 USD
CY2013Q2 cur Warrant Modification Expense
WarrantModificationExpense
2405206 USD
CY2012Q2 cur Warrant Modification Expense
WarrantModificationExpense
0 USD
CY2013Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
188317 USD
CY2012Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2013Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
-131 USD
CY2012Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 USD
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
-374 USD
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
-2573 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3016028 USD
CY2012Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6874 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-6251630 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-2376381 USD
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69864599 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54086405 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Share Based Compensation
ShareBasedCompensation
1073287 USD
us-gaap Share Based Compensation
ShareBasedCompensation
700992 USD
us-gaap Amortization Of Deferred Leasing Fees
AmortizationOfDeferredLeasingFees
239122 USD
us-gaap Amortization Of Deferred Leasing Fees
AmortizationOfDeferredLeasingFees
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
53422 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-177445 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4377 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-135367 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
232215 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
120082 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5392 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29610 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-237607 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-149692 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2397241 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
7551329 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
81362 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9832208 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4876501 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2352013 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2539534 USD
us-gaap Interest Paid
InterestPaid
175071 USD
us-gaap Interest Paid
InterestPaid
1454 USD
cur Issuance Of Warrants For Fees Related To Debt Issuance
IssuanceOfWarrantsForFeesRelatedToDebtIssuance
452187 USD
cur Issuance Of Warrants For Fees Related To Debt Issuance
IssuanceOfWarrantsForFeesRelatedToDebtIssuance
0 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
4876501 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-16331 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-430255 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-694529 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-213827 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1219 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-5420 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5872297 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4539288 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3722304 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
187521 USD
cur Issuance Of Common Stock For Vendor Services
IssuanceOfCommonStockForVendorServices
0 USD
cur Issuance Of Common Stock For Vendor Services
IssuanceOfCommonStockForVendorServices
180000 USD
cur Issuance Of Warrants For Vendor Services
IssuanceOfWarrantsForVendorServices
143478 USD
cur Issuance Of Warrants For Vendor Services
IssuanceOfWarrantsForVendorServices
0 USD
cur Common Stock For Executive Bonuses
CommonStockForExecutiveBonuses
0 USD
cur Common Stock For Executive Bonuses
CommonStockForExecutiveBonuses
141119 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
35000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-121978 USD
cur Issuance Of Common Stock Related To Debt Issuance Fees
IssuanceOfCommonStockRelatedToDebtIssuanceFees
396234 USD
cur Issuance Of Common Stock Related To Debt Issuance Fees
IssuanceOfCommonStockRelatedToDebtIssuanceFees
0 USD
cur Policy For Maximum Maturity Days Of Investments Considered As Cash Equivalents
PolicyForMaximumMaturityDaysOfInvestmentsConsideredAsCashEquivalents
P90D
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35000000 shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31100000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style=" FONT-SIZE: 10pt"><u>Use of Estimates</u></font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style=" FONT-SIZE: 10pt">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The condensed financial statements include significant estimates for the value and expected economic life of our licensed technology, our net operating loss for tax purposes, <font style=" FONT-SIZE: 10pt">the fair value of our derivative instruments and our share-based compensation related to employees and directors, consultants and investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</font></font></div> </div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28000000 shares
CY2012Q3 cur Class Of Warrant Or Right Exercise Price Of Warrants Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsIssued
1.25
CY2012Q3 cur Class Of Warrant Or Right Exercise Price Of Warrants Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsIssued
0.50
CY2012Q1 cur Class Of Warrant Or Right Exercise Price Of Warrants Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsIssued
1.02
CY2013Q1 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
2000000 USD
CY2013Q2 us-gaap Debt Instrument Interest Rate At Period End
DebtInstrumentInterestRateAtPeriodEnd
0.1100 pure
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2016-06-30
cur Debt Instrument Weighted Average Interest Rate
DebtInstrumentWeightedAverageInterestRate
0.11 pure
us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
maturity can both be extended by three (3) months if the additional borrowing capacity is drawn on.
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
7551000 USD
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
350650 shares
CY2013Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
8000000 USD
CY2013Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
32000 shares
CY2012Q3 cur Shares Issued Direct Placement
SharesIssuedDirectPlacement
7000000 shares
CY2012Q1 cur Shares Issued Direct Placement
SharesIssuedDirectPlacement
5200000 shares
CY2012Q1 cur Warrants Issued During Period
WarrantsIssuedDuringPeriod
5200000 shares
CY2013Q1 cur Class Of Warrant Or Right Exercise Price Of Warrants Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsIssued
1.25
CY2012Q4 us-gaap Share Price
SharePrice
1.02
CY2012Q3 us-gaap Share Price
SharePrice
1.00
CY2012Q3 us-gaap Share Price
SharePrice
0.40
CY2012Q1 us-gaap Share Price
SharePrice
1.00
CY2013Q1 us-gaap Share Price
SharePrice
1.25
CY2013Q1 cur Stock Issued During Period Share From Warrants In Conjunction With Debt Transaction
StockIssuedDuringPeriodShareFromWarrantsInConjunctionWithDebtTransaction
1297607 shares
CY2012Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7000000 USD
CY2012Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2760000 USD
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5200000 USD
CY2012Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
350000 shares
CY2012Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
300000 shares
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
350650 shares
CY2012Q3 cur Common Stock In Public Offering
CommonStockInPublicOffering
6900000 shares
CY2012Q4 cur Warrants And Shares Issued Value Net
WarrantsAndSharesIssuedValueNet
204000 USD
CY2013Q1 cur Warrants Expiration Date
WarrantsExpirationDate
2020-03-31
CY2012Q1 cur Warrants And Shares Issued Value Net
WarrantsAndSharesIssuedValueNet
4877000 USD
CY2012Q3 cur Warrants And Shares Issued Value Net
WarrantsAndSharesIssuedValueNet
2441000 USD
CY2012Q3 cur Warrants And Shares Issued Value Net
WarrantsAndSharesIssuedValueNet
6368000 USD
CY2013Q1 cur Warrants And Shares Issued Value Net
WarrantsAndSharesIssuedValueNet
323000 USD
CY2012Q4 cur Stock Issued During Period Share From Warrants Exercised
StockIssuedDuringPeriodShareFromWarrantsExercised
200000 shares
CY2013Q1 cur Stock Issued During Period Share From Warrants Exercised
StockIssuedDuringPeriodShareFromWarrantsExercised
258000 shares
CY2012Q1 cur Warrants Expiration Date
WarrantsExpirationDate
2022-01-06
CY2012Q4 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
25000 shares
CY2013Q1 cur Warrants Issued During Period
WarrantsIssuedDuringPeriod
258000 shares
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
596576 USD
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
330713 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1502579 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14787287 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16289866 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11577210 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
16289866 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.98
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.12
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1926000 USD
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5460844 USD
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3225952 USD
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5460844 USD
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.25
CY2012Q4 cur Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms
P6Y1M6D
CY2013Q2 cur Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2013Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
16289866 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.90
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.90
CY2013Q2 us-gaap Gain Contingency Unrecorded Amount
GainContingencyUnrecordedAmount
250000 USD

Files In Submission

Name View Source Status
R3.xml Edgar Link unprocessable
0001144204-13-043952-index-headers.html Edgar Link pending
0001144204-13-043952-index.html Edgar Link pending
0001144204-13-043952.txt Edgar Link pending
0001144204-13-043952-xbrl.zip Edgar Link pending
cur-20130630.xml Edgar Link completed
cur-20130630.xsd Edgar Link pending
cur-20130630_cal.xml Edgar Link unprocessable
cur-20130630_def.xml Edgar Link unprocessable
cur-20130630_lab.xml Edgar Link unprocessable
cur-20130630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
v350684_10q.htm Edgar Link pending
v350684_ex31-1.htm Edgar Link pending
v350684_ex31-2.htm Edgar Link pending
v350684_ex32-1.htm Edgar Link pending
v350684_ex32-2.htm Edgar Link pending
v350684_ex4-26.htm Edgar Link pending